Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical receives market approval in Italy
Non-regulatory
Sedana Medical AB (publ) has received market approval for Sedaconda[®] (isoflurane) for inhaled seda…
Invitation to presentation of Sedana Medical’s fourth quarter and Year-End Report 2022
Non-regulatory
Sedana Medical AB (publ) plans to present its fourth quarter and Year-End Report for 2022 in an audi…
First day of trading in Sedana Medical’s shares on Nasdaq Stockholm
Regulatory
Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasda…
Financial Calendar
| Year-End Report 2022 | 16 February 2023 | 07:00 |
| Annual Report 2022 | 03 April 2023 | 07:00 |
